Modeling of treatment response to erythropoiesis-stimulating agents as a function of center- and patient-related variables: results from the Anemia Cancer Treatment (ACT) study-Reference-Cited by-同舟云学术

Modeling of treatment response to erythropoiesis-stimulating agents as a function of center- and patient-related variables: results from the Anemia Cancer Treatment (ACT) study

Published:2009-10 Issue:10 Volume:20 Page:1714-1721
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Aapro M.,Ludwig H.,Bokemeyer C.,MacDonald K.,Soubeyran P.,Turner M.,Albrecht T.,Abraham I.

Funder

F. Hoffmann-La Roche

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/20/10/1714/612691/mdp063.pdf

Reference30 articles.

1. Erythropoietin analogues: an unnecessary class of drugs;Anonymous;Lancet Oncol,2008

2. Erythropoietins should be used according to guidelines;Aapro;Lancet Oncol,2008

3. Erythropoietin-stimulating agents: favorable safety profile when used as indicated;Nowrousian;Strahlenther Onkol,2008

5. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review;Caro;Cancer,2001

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of anemia management with EPO on psychologic distress in cancer patients: results of a multicenter patient survey;Future Oncology;2014-01

2. Modeling of treatment response to erythropoiesis-stimulating agents in older (age≥70years) and younger (age<70years) patients with cancer and anemia: Findings from the Anemia Cancer Treatment study;Journal of Geriatric Oncology;2013-04

3. Clinical safety of biosimilar recombinant human erythropoietins;Expert Opinion on Drug Safety;2012-08-13

4. Real-world effectiveness of valsartan on hypertension and total cardiovascular risk: review and implications of a translational research program;Vascular Health and Risk Management;2011-03

5. RETRA: evaluating the transfusion rate with darbepoetin alfa 500 µg every 3 weeks in anaemic cancer patients receiving chemotherapy;Current Medical Research and Opinion;2010-12-20